RT Journal Article
T1 Pangenome of Acinetobacter baumannii uncovers two groups of genomes, one of them with genes involved in CRISPR/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation.
A1 Mangas, Eugenio L
A1 Rubio, Alejandro
A1 Álvarez-Marín, Rocío
A1 Labrador-Herrera, Gema
A1 Pachón, Jerónimo
A1 Pachón-Ibáñez, María Eugenia
A1 Divina, Federico
A1 Pérez-Pulido, Antonio J
K1 Acinetobacter baumannii
K1 CRISPR
K1 bacterial genomics
K1 biofilm
K1 plasmids
K1 toxin–antitoxin
AB Acinetobacter baumannii is an opportunistic bacterium that causes hospital-acquired infections with a high mortality and morbidity, since there are strains resistant to virtually any kind of antibiotic. The chase to find novel strategies to fight against this microbe can be favoured by knowledge of the complete catalogue of genes of the species, and their relationship with the specific characteristics of different isolates. In this work, we performed a genomics analysis of almost 2500 strains. Two different groups of genomes were found based on the number of shared genes. One of these groups rarely has plasmids, and bears clustered regularly interspaced short palindromic repeat (CRISPR) sequences, in addition to CRISPR-associated genes (cas genes) or restriction-modification system genes. This fact strongly supports the lack of plasmids. Furthermore, the scarce plasmids in this group also bear CRISPR sequences, and specifically contain genes involved in prokaryotic toxin-antitoxin systems that could either act as the still little known CRISPR type IV system or be the precursors of other novel CRISPR/Cas systems. In addition, a limited set of strains present a new cas9-like gene, which may complement the other cas genes in inhibiting the entrance of new plasmids into the bacteria. Finally, this group has exclusive genes involved in biofilm formation, which would connect CRISPR systems to the biogenesis of these bacterial resistance structures.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14956
UL http://hdl.handle.net/10668/14956
LA en
DS RISalud
RD Jun 1, 2025